The rising price of cancer drugs- a newold problem?

JAMA Oncology

Volumn 3, Issue 2, 2017, Pages 277-278

  Prasad, Vinay ^a,b   Wang, Ruibin ^c   Afifi, Salma H ^d   Mailankody, Sham ^d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85018692836     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.4275     Document Type: Letter

References (7)

1. McCarthyM. Drug's 5000% price rise puts spotlight on soaring US drug costs. BMJ. 2015;351:h5114.
2. Koons C, Keller M, Langreth R. How EpiPen's Price Rose. http://www .bloomberg.com/graphics/2016-epipen-pricing/. Accessed September 1, 2016.
3. Hornberger J. Assigning value to medical algorithms: implications for personalized medicine. Per Med. 2013;10(6):577-588.
4. Centers for Medicare and Medicaid Services. Medicare Part B Drug Average Sales Price. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2015ASPFiles.html. Accessed September 1, 2016.
5. Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst. 2009;101(15): 1044-1048.
6. Experts in Chronic Myeloid Leukemia. The price of drugs for chronicmyeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121(22): 4439-4442.
7. Mailankody S, Prasad V. Five years of cancer drug approvals: innovation, efficacy, and costs. JAMA Oncol. 2015;1(4):539-540.